Patents by Inventor Paolo Stabile

Paolo Stabile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220298116
    Abstract: Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5?-Chloro-2?-hydroxy[1,1?-biphenyl]-3-carboxylic acid alkaline metal salt of formula: wherein A is an alkaline metal.
    Type: Application
    Filed: July 4, 2019
    Publication date: September 22, 2022
    Applicant: F.l.S. - FABBRICA ITALIANA SINTETICI S.P.A
    Inventors: Paolo STABILE, Floriana SEMERARO
  • Patent number: 11434197
    Abstract: The present invention relates to a process for the preparation of Droxidopa by means of an improved enzymatic reduction of a compound of formula (II): (II), wherein R1, R2 is independent hydrogen, acetyl, R3 is hydrogen, a C1-C4 linear or branched alkyl group and R4 is hydrogen or an amine protecting group.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: September 6, 2022
    Assignee: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Stefano Fogal, Paolo Stabile, Pierluigi Padovan, Matteo De Poli, Angelo Restelli
  • Patent number: 11267791
    Abstract: Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 8, 2022
    Assignee: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Nicolas Tesson, Jordi De Mier Vinue, Paolo Stabile, Pierluigi Padovan, Matteo De Poli, Angelo Restelli
  • Patent number: 11214547
    Abstract: Object of the present invention is a better crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D, stable, suitable for pharmaceutical purposes, and with the highest solubility in water and excellent non-hygroscopicity, then the related process and intermediates thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: January 4, 2022
    Assignee: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Nicolas Tesson, Jordi De Mier Vinue, Paolo Stabile, Pierluigi Padovan, Matteo De Poli, Angelo Restelli
  • Publication number: 20210284611
    Abstract: Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.
    Type: Application
    Filed: July 25, 2019
    Publication date: September 16, 2021
    Applicant: F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Nicolas TESSON, Jordi DE MIER VINUE, Paolo STABILE, Pierluigi PADOVAN, Matteo DE POLI, Angelo RESTELLI
  • Publication number: 20210198211
    Abstract: Object of the present invention is a better crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D, stable, suitable for pharmaceutical purposes, and with the highest solubility in water and excellent non-hygroscopicity, then the related process and intermediates thereof.
    Type: Application
    Filed: July 25, 2019
    Publication date: July 1, 2021
    Applicant: F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Nicolas TESSON, Jordi DE MIER VINUE, Paolo STABILE, Pierluigi PADOVAN, Matteo DE POLI, Angelo RESTELLI
  • Publication number: 20210163401
    Abstract: The present invention relates to a process for the preparation of Droxidopa by means of an improved enzymatic reduction of a compound of formula (II): (II), wherein R1, R2 is independent hydrogen, acetyl, R3 is hydrogen, a C1-C4 linear or branched alkyl group and R4 is hydrogen or an amine protecting group.
    Type: Application
    Filed: June 7, 2019
    Publication date: June 3, 2021
    Applicant: F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Stefano FOGAL, Paolo STABILE, Pierluigi PADOVAN, Matteo DE POLI, Angelo RESTELLI
  • Patent number: 9688658
    Abstract: An efficient process for increasing the optical purity of the active pharmaceutical ingredient Esomeprazole, by means of a substantially quantitative and selective precipitation and removal of Omeprazole is provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: June 27, 2017
    Assignee: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Paolo Stabile, Diego Rasia, Nicola Faccin, Moreno Bertolazzi
  • Patent number: 9428486
    Abstract: Object of the present invention is an improved process for the preparation of Esomeprazole (S)-BINOL complex which is a key intermediate for the synthesis of Esomeprazole and salts thereof.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 30, 2016
    Assignee: F.I.S.—Fabbrica Italiana Sintetici S.p.A.
    Inventors: Paolo Stabile, Moreno Bertolazzi, Nicola Faccin, Diego Rasia
  • Publication number: 20160244428
    Abstract: Object of the present invention is an improved process for the preparation of Esomeprazole (S)-BINOL complex which is a key intermediate for the synthesis of Esomeprazole and salts thereof.
    Type: Application
    Filed: June 22, 2015
    Publication date: August 25, 2016
    Inventors: PAOLO STABILE, MORENO BERTOLAZZI, NICOLA FACCIN, DIEGO RASIA
  • Publication number: 20140206882
    Abstract: The present invention relates to an efficient process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of the synthesis of Etoricoxib. Water is employed as reaction medium.
    Type: Application
    Filed: June 21, 2013
    Publication date: July 24, 2014
    Inventors: Paolo Stabile, Marco Galvagni
  • Patent number: 8765962
    Abstract: The present invention relates to an efficient process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of the synthesis of Etoricoxib. Water is employed as reaction medium.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: July 1, 2014
    Assignee: F.I.S.—Fabrica Italiana Sintetici S.p.A.
    Inventors: Paolo Stabile, Marco Galvagni
  • Patent number: 8742118
    Abstract: Methods for the synthesis of 2-alkoxy-5-(pyridin-2-yl)pyridine of formula I or salts thereof are provided.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: June 3, 2014
    Assignee: F.I.S.—Fabbrica Italiana Sintetici S.p.A.
    Inventors: Francesco Fontana, Paolo Stabile
  • Patent number: 8664402
    Abstract: A process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methyl sulfonyl)phenyl]ethanone, an intermediate of the synthesis of Etoricoxib. The synthesis of the intermediates useful for such preparation is also described.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: March 4, 2014
    Assignee: F.I.S. Fabbrica Italiana Sintetici S.p.A.
    Inventors: Andrea Castellin, Paolo Stabile, Francesco Fontana, Ottorino De Lucchi, Andrea Caporale, Stefano Tartaggia
  • Publication number: 20120232281
    Abstract: A process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methyl sulfonyl)phenyl]ethanone, an intermediate of the synthesis of Etoricoxib. The synthesis of the intermediates useful for such preparation is also described.
    Type: Application
    Filed: January 11, 2012
    Publication date: September 13, 2012
    Inventors: Andrea Castellin, Paolo Stabile, Francesco Fontana, Ottorino De Lucchi, Andrea Caporale, Stefano Tartaggia
  • Publication number: 20090023757
    Abstract: The present invention relates to a novel process for preparing compounds of formula (IA), which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors, from intermediate compounds of formula (I), by a coupling reaction catalysed by copper.
    Type: Application
    Filed: April 6, 2006
    Publication date: January 22, 2009
    Inventors: Daniele Andreotti, Sergio Bacchi, Monica Delpogetto, Simone Guelfi, Alcide Perboni, Arianna Ribecai, Simone Spada, Paolo Stabile, Marsia Tampieri
  • Publication number: 20080312444
    Abstract: The present invention relates to a novel process for preparing compounds of formula (IA), which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors, from intermediate compounds of formula (I), by a coupling reaction catalysed by copper.
    Type: Application
    Filed: April 6, 2006
    Publication date: December 18, 2008
    Inventors: Sergio Bacchi, Monica Delpogetto, Simone Guelfi, Alcide Perboni, Arianna Ribecai, Paolo Stabile, Marsia Tampieri